J Cell Physiol:结直肠癌患者靶向BRAF治疗的现状与未来

2017-05-30 月下荷花 肿瘤资讯

可用于结直肠癌(CRC)的靶向药物并不多,且在面对BRAF突变患者时,靶向药疗效不佳。伊朗Bahrami 教授在J CELL PHYSIOL杂志上发文总结了BRAF突变结直肠癌治疗的现状与未来,包括潜在的靶向治疗方法。结直肠癌分子分类学者很早就提出CRC的多步骤发生过程,即上皮细胞累积多个分子突变后转化为恶性细胞。然而不同肿瘤间遗传学和表观遗传学事件差别很大,因此CRC并不是单一疾病。事实上,

可用于结直肠癌(CRC)的靶向药物并不多,且在面对BRAF突变患者时,靶向药疗效不佳。伊朗Bahrami 教授在J CELL PHYSIOL杂志上发文总结了BRAF突变结直肠癌治疗的现状与未来,包括潜在的靶向治疗方法。

结直肠癌分子分类

学者很早就提出CRC的多步骤发生过程,即上皮细胞累积多个分子突变后转化为恶性细胞。然而不同肿瘤间遗传学和表观遗传学事件差别很大,因此CRC并不是单一疾病。

事实上,可以根据分子改变分类,预测疾病自然过程、对治疗反应以及评估病因学和分子亚型间的关系,后者还可用于优化预防策略。不过在确定分子分类标志时有一些关键问题需要注意:

首先,分子面貌是否可以反应基因组变化,要注意混杂因素;

其次,分子改变本身是否可启动癌症或促进癌症进展。

结直肠癌中的BRAF突变

RAF家族蛋白包括ARAF、BRAF和CRAF(RAF-1)。BRAF基因编码MAPK途径的蛋白激酶,600密码子突变导致BRAF蛋白结构性活化,诱导MAPK途径活化。BRAF错义突变发生于5-10%转移性结直肠癌(MCRCs),患者对标准化疗反应差,中位PFS和OS只有2.5个月和不足1年,因此迫切需要新的治疗手段。

BRAF突变与微卫星不稳定和CpG岛甲基化表型(CIMP)相关,而KRAS突变最常见于微卫星稳定和CIMP-低肿瘤。CIMP癌症对不同化疗(CT)的反应如何?假说认为CIMP肿瘤抑制γ-谷氨酰水解酶,增加细胞内叶酸水平,对5-FU治疗反应更佳。尽管假说提出CRCs会从辅助化疗中获益,但实际上研究结论不一致,甚至截然相反。

造成相互矛盾的结果可能与如下因素有关:定义的不同,CIMP标志的界值不同,选择的基因组合不同,评估CIMP状态使用技术的不同所致。目前NCCN指南中仍不推荐II期CIMP肿瘤化疗。由于数据不统一,CIMP的5-FU治疗预测作用仍不清楚,需要更多研究。

有研究显示BRAF是生存减低的独立因素,也是预测抗EGFR治疗是否获益的标志。回顾性研究评估了BRAF突变MCRC中抗EGFR治疗的作用,结果BRAF突变导致患者对抗EGFR治疗反应极差,显示出不良预后,而贝伐单抗与FOLFOXIRI联合能改善PFS和OS。这就提出如何克服BRAF突变MCRC中的抗EGFR治疗耐药。

针对BRAF途径的靶向治疗

为了克服BRAF突变MCRC中抗EGFR治疗耐药,进行了大量研究,针对BRAF途径、可能有助于克服抗EGFR治疗耐药的靶向药物包括索拉非尼,临床前研究显示能抑制包括BRAF在内的多种激酶活性;GDC-0879是选择性RAF抑制剂,临床前研究显示能持续抑制肿瘤并获得更长OS。

已进入临床研究的药物包括PLX4720 (威罗非尼),是BRAF V600E蛋白的选择性抑制剂,对野生型BRAF无抑制作用,与黑色素瘤中的良好疗效相反,威罗非尼靶向CRC中BRAF突变的治疗反应率很低;PLX4032也是小分子BRAFV600E抑制剂,治疗MCRC时反应率仅有5%;一项I期研究显示BRAF抑制剂达拉非尼治疗9例MCRC,只有1例显示OR;曲美替尼是MEK1/MEK2抑制剂(BRAF下游),治疗BRAF突变CRC疗效似乎欠佳。

单独BRAF抑制剂治疗MCRC的耐药机制

BRAFV600E突变CRC似乎对BRAF抑制剂天然耐药,根据是否依赖ERK信号途径对耐药机制分类,ERK依赖性耐药需要MEK1活性突变、COT过表达、NRAS活性突变、高CRAS活性和BRAFV600E不同片段拼接或表达;ERK非依赖性机制包括IGF1R活化,HGF高度扩增和PI3K及PDGFRβ过表达。同一患者不同转移灶可能共存多个耐药机制。

BRAFV600E突变CRC中,BRAF基因扩增是已知的BRAF和MEK耐药机制;有研究发现EGFR在BRAF抑制治疗耐药中具有关键作用,因为RAF抑制时可导致EGFR快速反馈性活化,研究还发现CRC细胞较黑色素瘤细胞携带更多磷酸化的EGFR以及通过EGFR再活化的MAPK途径。

克服BRAF抑制耐药需要多途径的联合靶向治疗

由于不同受体酪氨酸激酶(RTK)信号瀑布中存在交叉,注定靶向单一靶点无效,采用单药阻滞时,会通过其它途径避开阻滞,因此联合BRAF抑制与抗EGFR、MEK抑制或PI3K抑制可能会克服对BRAF抑制的原发耐药。

已有报道达拉非尼+曲美替尼双抑制能改善治疗活性,5/43患者部分缓解,24/43例疾病稳定。一项I期研究显示选择性BRAFV600E抑制剂LGX818联合西妥昔单抗±PI3K抑制剂(alpelisib)治疗54例BRAF突变MCRC,三药组的RR和PFS较二药组改善。一项I/II期研究中采用达拉非尼+帕尼单抗、曲美替尼+帕尼单抗和达拉非尼+帕尼单抗+曲美替尼治疗,结果显示三药联合治疗较二药疗效更佳。

Yaeger的研究显示帕尼单抗+威罗非尼可使部分BRAF突变MCRC获得缓解,该研究进一步测序分析显示WNT途径改变在过度突变的BRAF突变CRC中并不多见,WNT途径是通过锯齿状瘤发生肿瘤,而传统途径是由腺瘤发展为肿瘤;5例显示有TP53改变,说明P53失活在BRAF突变CRC中发挥作用;2例为PI3K途径活性突变,对治疗反应不明显,提示PI3K活化会影响EGFR和RAF联合治疗的疗效。

最近研究显示获得性RAF抑制耐药是由于ERK未能充分抑制所致,研究显示威罗非尼+帕尼单抗能明显阻滞ERK信号,但程度变化大,威罗非尼的药物研究显示ERK抑制是抑制肿瘤生长所必需,即便有少量残留也足以维持肿瘤生长,同时发现细胞周期素D1抑制不完全,因此细胞周期素D1有可能用作不完全阻滞的标志。不过这些都需要进一步研究。

一项Ib研究采用威罗非尼+依立替康+西妥昔单抗治疗,下调因BRAF抑制导致的EGFR活化,ORR有改善,据此一项II期SWOG 1406研究将进一步评估。另一项II期MO29112研究正在进行,FOLFOX+贝伐单抗治疗后无进展患者随机接受5-FU/叶酸+西妥昔单抗+威罗非尼或氟脲嘧啶+贝伐单抗维持治疗,评估其疗效与安全性。

BRAF抑制联合PI3K/mTOR双重抑制可诱导肿瘤更好的缩小。有研究显示BRAF突变MCRC接受RAF+EGFR抑制剂或RAF+MEK抑制剂治疗产生获得性耐药时发生BRAF扩增、ARAF突变、KRAS扩增或MEK1突变,加入ERK抑制剂能抑制MAPK活化克服耐药,因此需要更多联合治疗的研究来改善治疗有效性。MET基因表达可能也是BRAF和EGFR抑制治疗获得性耐药的机制之一。

研究显示全RAF抑制剂对BRAF突变黑色素瘤和CRC细胞株有治疗作用,对选择性BRAF抑制剂或BRAF+MEK抑制耐药的CRC也有疗效。全RAF抑制剂为复发患者提供了二线治疗可能。

结语

BRAFV600E突变是CRC的预测标志和不良预后标志,靶向BRAF治疗目前还不成熟,主要由于耐药或其它途径活化所致,根据这一机制提出同时靶向几个异常途径的治疗策略。目前用于靶向BRAFV600E突变的药物有PLX3603、LGX818、达拉非尼、威罗非尼和PLX4032,但需要与PI3K、MEK或EGFR抑制剂联合才能发挥作用。需要更多研究探讨这种治疗策略的价值,更好的选择患者使其从治疗中获益。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-10-13 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-07-17 1e1263e3m20(暂无匿称)

    学习了多谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-06-03 日月生辉

    靶向治疗药是个体化疗治疗,注定有效率不会很高!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-06-02 luominglian113

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-06-01 zhaojie88
  8. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-05-31 ylzr123

    感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1869977, encodeId=f74b18699e732, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Dec 02 22:50:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788807, encodeId=4af01e88807e1, content=<a href='/topic/show?id=866d1421e4c' target=_blank style='color:#2F92EE;'>#Physio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14217, encryptionId=866d1421e4c, topicName=Physio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Jan 12 09:50:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960236, encodeId=90b0196023657, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Oct 13 00:50:00 CST 2017, time=2017-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223315, encodeId=91dd223315f3, content=学习了多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Mon Jul 17 21:54:37 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205882, encodeId=728420588250, content=靶向治疗药是个体化疗治疗,注定有效率不会很高!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat Jun 03 08:05:29 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205671, encodeId=f8832056e1eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Fri Jun 02 15:38:48 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354963, encodeId=7ea41354963a5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452912, encodeId=7f3b145291264, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Thu Jun 01 04:50:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204787, encodeId=945f204e87c6, content=感谢小编为我们精心准备了如此精辟的精神大餐,小编辛苦了,点个赞吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Wed May 31 11:34:02 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=204773, encodeId=96d1204e739c, content=学习一下知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed May 31 10:32:53 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-05-31 flysky120

    学习一下知识

    0

相关资讯

AIM:临床医生需警惕间期结直肠癌的种族/民族差异

间期结直肠癌(Interval colorectal cancer,intervalCRC)也称为结肠镜后结直肠癌(post-colonoscopy colorectal cancer, PCCRC),定义为筛查或监测检查未发现,而在推荐的下一次检查日期之前发生的结直肠癌。在美国,间期CRC占所有CRC患者的3%-8%。但关于间期CRC的种族/民族数据却很少。因此,来自美国的研究人员进行了一项研究

WJG:多吃蔬菜和水果对身体好?那可未必!

长久以来,我们印象中只是觉得多吃蔬菜水果对身体好,可是大部分人却不知道蔬菜水果对人究竟有多大的好处。实际上,蔬菜水果除了为人体提供必要的维生素和其他微量元素外,更重要的是为肠道的蠕动提供了大量的非可溶性膳食纤维,而非可溶性膳食纤维除了促进肠道蠕动,防止便秘外,其在肠道内还会被细菌分解为短链脂肪酸,比如丁酸,而这些短链脂肪酸对于肠道正常黏膜细胞来说可以促进其代谢,而对于肿瘤细胞,则会促进其凋亡,这也

CLIN CANCER RES:转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性

尽管RAS-BRAF野生型及HER2/MET阴性转移性结直肠癌患者通常对抗EGFR单克隆抗体有反应,但获得性耐药几乎无法避免。EGFR阻滞剂耐药的机制包括KRAS、NRAS和EGFR胞外区突变以及HER2/MET改变。但是,分子异质性如何影响患者克隆演变尚不清楚。CLIN CANCER RES近期发表了一篇文章,分析接受过抗EGFR抗体治疗的转移性结直肠癌患者肿瘤组织及血液分子特征。

BJC:合并症可推迟结直肠癌的诊断时间,延误治疗!

先前存在的非癌症临床表现可能使结直肠癌诊断复杂化并延迟。该研究主要目的是评估合并症对结直肠癌的诊断的影响情况。

JCO:Non-V600 BRAF突变应成为转移性结直肠癌新的临床亚型

在评估转移性结直肠癌患者病情时,分子学检测已成为不可缺少的一部分。新一代测序技术(NGS)通常会发现没有明确临床或预后影响的突变,其中codon600以外的BRAF突变(non-V600BRAF突变)就是其中之一。

CCLM:miR-16在结肠直肠腺癌诊断和预后中的应用

结肠直肠腺癌是胃肠道最常见的恶性肿瘤之一,也是西方国家第二大癌症相关死亡原因之一。miR-16广泛参与癌症进展。在本研究中,来自雅典国家和卡波治理大学生物化学与分子生物学系的研究人员对miR-16在结肠直肠腺癌中的潜在诊断和预后效用进行了研究。